What is it about?
Melanoma is a skin malignancy that continues to increase in incidence worldwide. This study demonstrates that platelet-derived growth factor-receptor-α (PDGF-Rα) may represent a relevant target for novel antimelanoma approaches and indicates the fibroblast growth factor-2 (FGF-2)-derived peptide named FREG as potent PDGF-Rα agonist with significant in vitro and in vivo antimelanoma growth activity.
Featured Image
Photo by National Cancer Institute on Unsplash
Read the Original
This page is a summary of: The FGF-2-Derived Peptide FREG Inhibits Melanoma Growth In Vitro and In Vivo, Molecular Therapy, February 2011, Elsevier,
DOI: 10.1038/mt.2010.211.
You can read the full text:
Resources
Contributors
The following have contributed to this page
